Minimal Residual Disease in B-ALL|
UKAS Schedule of Accreditation, Accredited to ISO/IEC 17043:2010, Provider 7804
Identification of minimal residual disease in B-ALL
PURPOSE OF PROGRAMME:
To assess a laboratory's ability to minimal residual disease using flow cytometry.
|the programme covers a range of leukaemia antigens specific to b-all||Percentage size of minimal residual disease population|
MATERIAL PROVIDED: Stabilised leukaemic blood diluted in stabilised whole blood
DISTRIBUTIONS PER YEAR: 4
SAMPLES PER DISTRIBUTION: 3
FREQUENCY OF DISTRIBUTION: 3 monthly as per Trial Schedule (Please note – The Trial Schedule is a guide only and is subject to change)
PROGRAMME OF ANALYSIS:
Results are entered online via the UK NEQAS LI website. Trials are live for 3 weeks. Results can be entered at any time during this period. Under exceptional circumstances late results are accepted at our discretion via email/fax.
Quantitative analysis based on the percentage minimal residual disease.
z scores using robust means and robust SDs with standard limits of +2 and +3 and -2 and -3 as per ISO 13528 A result between 2.0 and -2.0 would be classed as satisfactory. A result between >2.0 and 3.0 or <-2.0 and -3.0 is seen as an 'Action' result, which highlights a potential issue to the laboratory. Two 'Action' results in a period of 3 samples would result in classification as a 'Critical'. A result above 3.0 or below -3.0 is considered to be a 'Critical' result requiring immediate inves
Participant performance is monitored by means of a rolling n+1 sample window where n equals the number of samples per trial issue.
PERSISTENT POOR PERFORMANCE:
Three 'Critical' classifications in a 12 month period are classed as Persistent Unsatisfactory Performance.
The External Quality Assessment Scheme for Leucocyte Immunophenotyping was established by Professor David Barnett in 1986 at Northern General Hospital, Sheffield. In 1990 the Service became known as the UK National External Quality Assessment Service for Leucocyte Immunophenotyping. UK NEQAS LI is part of the Sheffield Teaching Hospitals NHS Foundation Trust.